| Literature DB >> 25999994 |
Fatemeh Bazarganipour1, Seyed Abdolvahab Taghavi1, Ali Montazeri2, Fazlollah Ahmadi3, Reza Chaman4, Ahmad Khosravi5.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) has been shown to cause a reduction in health-related quality of life (HRQOL). However, the relative degree of impairment in each domain differed among samples, and it was not clear which aspect of disease-specific HRQOL (modified polycystic ovary syndrome health-related quality of life questionnaire) was most negatively affected.Entities:
Keywords: Meta-analysis; Polycystic ovary syndrome; Quality of life; Review
Year: 2015 PMID: 25999994 PMCID: PMC4426142
Source DB: PubMed Journal: Iran J Reprod Med ISSN: 1680-6433
Figure 1Flowchart shows the systematic review evidence
Characteristics of the studies included in the systematic review
|
|
| 4.2 ± 1.1 | 3.8 ± 1.4 | 4.2 ± 1.38 | 5.85 ± 1.33 | 4.40 ± 1.36 | 3.98 ± 1.8 |
|
| 3.9 + 1.4 | 3.5 ± 1.5 | 3.77 ± 1.29 | 4.18 ± 1.70 | 4.07 ± 1.56 | 3.65 ± 1.48 | |
|
| 4.7 ± 1.4 | 4.3 ± 1.6 | 3.78 ± 1.63 | 4.33 ± 1.95 | 4.38 ± 1.95 | 3.35 ± 1.88 | |
|
| 2.9 ± 1.6 | 3.2 ± 1.6 | 3.28 ± 1.60 | 5.24 ± 2.21 | 3.89 ± 1.93 | 4.33 ± 2.04 | |
|
| 4.8 ± 1.8 | 4.1 ± 1.9 | 2.61 ± 1.58 | 6.20 ± 1.01 | 2.66 ± 1.80 | 2.94 ± 1.98 | |
|
| PCOSQ, BDI, HADS, GHQ | PCOSQ, BDI, HADS, GHQ, STAI | PCOSQ | PCOSQ | PCOSQ, SF-36, GHQ-28, PIQ | PCOSQ, SF-36 | |
|
| 2003 Rotterdam criteria | 2003 Rotterdam criteria | 1990 NIH | 2003 Rotterdam criteria | 1990 NIH | N/A | |
|
| 78.6 ± 31.3 (ng/dl) | N/A | N/A | N/A | N/A | 40 (43.5) | |
|
| 8.7 ± 4.9 | N/A | N/A | 8.39 ± 4.28 | N/A | 46 (50) | |
|
| 23.3 ± 4.8 | 24.7 ± 5.7 | N/A | 26.02 ± 4.03 | 33.6 ± 8.7 | 48 (54.2) | |
|
| Turkey | Turkey | Canada, UK, USA | Iran | Australia | UK | |
|
| 36 | 226 | 393 | 200 | 203 | 82 | |
|
| Prospective observational | Prospective Case-control | prospective randomized placebo-controlled blinded | observational cross-sectional | observational cross-sectional | observational cross-sectional | |
|
| Cinar et al (2012) | Cinar et al (2011) | Guyatt et al (2004) | Bazarganipour et al (2012) | Ching et al (2007) | Jones et al (2004$) | |
BMI>28
Excessive body hair
Testosterone >2
The scores of PCOSQ were transformed on a range from 0 (indicating worst health status) to 100 (best health status) for compare with the SF-36 in this study. We transformed to 0-6 again for comparison with another studies. Moreover, we add 1 to score of PCOSQ, because in another study range was1-7 but in this study was 0-6.
Quality of included studies
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Title and abstract | |||||||
| Indicate study design | No | No | No | No | No | ||
| Provide informative summary | |||||||
| Introduction | |||||||
| Explain scientific background and rationale | |||||||
| State specific objectives/hypotheses | |||||||
| Methods | |||||||
| Present key elements of study design | |||||||
| Describe setting, location, and relevant dates | |||||||
| Give eligibility criteria, selection/ follow-up methods | |||||||
| Give matching criteria | NA | NA | NA | NA | NA | ||
| Define outcomes, exposures, and confounders | |||||||
| Give assessment methods for all variables | |||||||
| Describe efforts to assess potential sources of bias | |||||||
| Explain how the study size was arrived at | No | No | No | No | |||
| Explain how variables were handled in analyses | |||||||
| Describe all statistical methods | |||||||
| Describe methods to examine subgroups/ interaction | NA | NA | NA | NA | NA | NA | |
| Explain how missing data were addressed | NA | NA | NA | NA | NA | ||
| Explain how loss to follow-up was addressed | NA | NA | NA | NA | NA | ||
| Explain how matching was addressed | NA | No | NA | NA | NA | NA | |
| Describe any sensitivity analyses | NA | NA | NA | NA | NA | NA | |
| Results | |||||||
| Report participant numbers at each study stage | |||||||
| Give reasons for nonparticipation at each stage | No | No | NA | No | |||
| Consider using a flow diagram | No | No | No | No | No | No | |
| Give study population characteristics | |||||||
| Indicate % missing for all variables | NA | NA | NA | NA | NA | ||
| Summarize follow-up time | NA | NA | NA | ||||
| Give unadjusted/adjusted estimates & precision | |||||||
| Give category bounds for categorized continuous variables | No | No | No | No | No | ||
| Consider translating RR estimates to absolute risk | NA | NA | NA | NA | NA | NA | |
| Discussion | |||||||
| Summarize key results | |||||||
| Discuss study limitations | No | No | |||||
| Give a cautious overall interpretation of results | |||||||
| Discuss generalizability of study results | |||||||
| Other information | |||||||
| Give source of funding and role of funders | No | No | |||||
NA: not applicable
Figure 2Forest plot of all included studies of HQROL in women with PCOS ( emotion domain)
Figure 6Forest plot of all included studies of HQROL in women with PCOS ( weight domain)
Figure 3Forest plot of all included studies of HQROL in women with PCOS ( menstrual domain)
Figure 4Forest plot of all included studies of HQROL in women with PCOS ( infertility domain)
Figure 5Forest plot of all included studies of HQROL in women with PCOS ( hirsutism domain)
Parameter estimates for meta-regression model
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| BMI | Emotion | 0.011 | 0.13 | 0.94 | -0.58 to 0.60 |
| Menstruation | -0.29 | 0.04 | 0.56 | -0.15 to 0.21 | |
| Infertility | -0.006 | -0.19 | 0.97 | -0.08 to 0.08 | |
| Hirsutism | -0.59 | 0.15 | 0.73 | -0.60 to 0.72 | |
| Weight | -0.22 | 0.16 | 0.31 | -0.93 to 0.49 |